Obesity and Diabetes

Jens Aberle; Anne Lautenbach; Svenja Meyhöfer; Sebastian M. Schmid; Lars Selig; Matthias Blüher

doi:10.1055/a-1284-6050

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2021; 129(S 01): S44-S51
DOI: 10.1055/a-1284-6050

German Diabetes Association: Clinical Practice Guidelines

Obesity and Diabetes

Jens Aberle

¹Section Endocrinology and Diabetology, University Obesity Centre Hamburg, University Hospital Hamburg-Eppendorf, Hamburg, Germany

,

Anne Lautenbach

¹Section Endocrinology and Diabetology, University Obesity Centre Hamburg, University Hospital Hamburg-Eppendorf, Hamburg, Germany

,

Svenja Meyhöfer

²Institute for Endocrinology & Diabetes, University of Lübeck, Department of Internal Medicine 1, Endocrinology & Diabetes, University of Lübeck, Lübeck, Germany

,

Sebastian M. Schmid

²Institute for Endocrinology & Diabetes, University of Lübeck, Department of Internal Medicine 1, Endocrinology & Diabetes, University of Lübeck, Lübeck, Germany

,

Lars Selig

³Nutrition Team/Nutrition Outpatient Clinic, University Hospital Leipzig, Leipzig, Germany

,

Matthias Blüher

⁴Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig, Leipzig, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Lindström J, Louheranta A, Mannelin M. et al. Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236
2 Knowler WC, Barrett-Connor E, Fowler SE. et al. Diabetes Prevention Program Research G: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
3 Lean ME, Powrie JK, Anderson AS. et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-233
4 Williamson DF, Thompson TJ, Thun M. et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504
5 Look ARG, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575
6 Eeg-Olofsson K, Cederholm J, Nilsson PM. et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009; 52: 65-73
7 Buse JB, Wexler DJ, Tsapas A. et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 487-493
8 Wang Z, Hoy WE. Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr 2004; 58: 888-893
9 Pischon T, Boeing H, Hoffmann K. et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120
10 German Nutrition Society (DGE) e.V. Eat and drink wholefood according to the 10 rules of the DGE. 2017 https://www.dge.de/nutritional practice/full-fledged nutrition/10-rules of the DGE/
11 German Obesity Society (DAG) e. V.; German Diabetes Society (DDG); German Society for Nutrition (DGE) e. V.; German Society for Nutritional Medicine (DGEM). Interdisciplinary Quality Guideline S3 for “Prevention and Therapy” of Obesity - Long Version. German Medical Association (BÄK); National Association of Statutory Health Insurance Physicians (KBV); Association of Scientific Medical Societies (AWMF). 2014
12 Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-161
13 Evert AB, Dennison M, Gardner CD. et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019; 42: 731-754
14 Reynolds AN, Akerman AP, Mann J. Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses. PLoS Med 2020; 17: e1003053
15 Landgrave R, Aberle J, Birkenfeld AL. et al. Therapy of type 2 diabetes. Diabetologie 2019; 14: 144-167
16 Lean ME, Leslie WS, Barnes AC. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, clusterrandomised trial. Lancet 2018; 391: 541-551
17 Gregg EW, Chen H, Wagenknecht LE. et al. Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. JAMA 2012; 308: 2489
18 National Care Guideline Therapy of Type 2 Diabetes. - Long version. 2020; 1st edition. Version 4. https://doi.org/10.6101/AZQ/000213
19 Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev 2006; 7: 183-200
20 Piercy KL, Troiano RP, Ballard RM. et al. The Physical Activity Guidelines for Americans. JAMA 2018; 320: 2020
21 van Can J, Sloth B, Jensen CB. et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014;
22 Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314: 687-699
23 Pi-Sunyer X, Astrup A, Fujioka K. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373: 11-22
24 Golay A. Metformin and body weight. Int J Obes 2008; 32: 61-72
25 O’Neil PM, Birkenfeld AL, McGowan B. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392: 637-649
26 Frias JP, Nauck MA, Van J. et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018; 392: 2180-2193
27 Rubino F, Nathan DM, Eckel RH. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016; 39: 861-877
28 S3 guideline: Surgery for obesity and metabolic diseases. 2018 https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_ Surgery-Adiposity-metabolic diseases_2018-02.pdf
29 Flum DR, Belle SH, King WC. et al. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361: 445-445
30 Birkmeyer NJ, Dimick JB, Share D. et al. Michigan Bariatric Surgery Collaborative. Hospital complication rates with bariatric surgery in Michigan. JAMA 2010; 304: 435-444
31 Aberle J, Reining F, Klinge A. et al. Metformin After Bariatric Surgery - an Acid Problem. Exp Clin Endocrinol Diabetes 2012; 120: 152-153